CCXI Summary
- NASDAQ >
- CCXI
Ticker | CCXI |
---|---|
Description | CHEMOCENTRYX INC |
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. | |
Exchange | NASDAQ |
Type | Stock |
Sector | Healthcare |
Employees | 133 |
Next Earnings Date | November 8th, 2022 |
IV | 11.894328% |
IV Percentile | 2nd |
IV Rank | 0.04% |
IV Skew | -10.006817 |
IV Skew Percentile | 12th |
IV Skew Sentiment | Bullish |
Option Volume | 638 |
Volume | 2,891,876 |
Price | $50.60 |
Previous Close | $50.60 |
52-Week High | $51.06 |
52-Week Low | $13.11 |
50-Day Moving Avg. | $28.70 |
200-Day Moving Avg. | $25.10 |
10-Day Avg. Volume | 9,948,318 |
20-Day Avg. Volume | 3,978,599 |
30-Day Avg. Volume | 3,824,589 |
3-Month Avg. Volume | 2,080,386 |
EPS | -$2.01 |
Outstanding Shares | 71,355,872 |
Market Capitalization | $3,621,605,800 |
Currency | USD |
Updated | August 12th, 2022 |